Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03778073 · ClinicalTrials.gov registry record · Phase 1
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
A Phase 1 study, sponsored by TG Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT03778073 is a Phase 1 study that was terminated before completion, run by TG Therapeutics. The registered enrollment target is 18 participants.
The verdict
NCT03778073, a Phase 1 study, was terminated before completion, sponsored by TG Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.
Interventions
- DRUG Cosibelimab
- DRUG Cosibelimab + Ublituximab + Bendamustine combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-04-17 |
| Est. Completion | 2022-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03778073
The ClinicalTrials.gov registry entry for NCT03778073 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TG Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cosibelimab is the first listed.
NCT03778073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03778073 about?
NCT03778073 is a clinical study titled "Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma". Phase 1 open label, multi-center, dose-escalation study for individuals with relapsed or refractory B-cell Non Hodgkin's Lymphoma.
What is the current status of trial NCT03778073?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2019-04-17. Estimated completion is 2022-08-01.
What interventions are being tested in trial NCT03778073?
The interventions under investigation include: Cosibelimab (DRUG), Cosibelimab + Ublituximab + Bendamustine combination (DRUG).
Who is sponsoring clinical trial NCT03778073?
This trial is sponsored by TG Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.